Rapamycin for Longevity: Human Evidence, Mouse Data & Risks

Clinical status#

Rapamycin is the common research name for sirolimus, a prescription mTOR inhibitor. It is not a dietary supplement, and FDA-approved sirolimus labeling does not establish an indication for slowing ageing or extending life in healthy people.

This page explains the research; it does not provide a protocol, dose, prescriber referral, or recommendation to use sirolimus off-label.

What is established#

The US prescribing label includes sirolimus uses in renal-transplant rejection prevention and treatment of lymphangioleiomyomatosis. Other mTOR inhibitors have their own indications; those should not be attributed to sirolimus as a class shortcut.

The label also carries substantial warnings, including increased susceptibility to infection and lymphoma or other malignancies in immunosuppressed transplant populations. Additional warnings cover impaired wound healing, hyperlipidemia, renal effects, proteinuria, pneumonitis, interactions, and embryo-fetal harm.

Read the current label rather than relying on a longevity-clinic summary: DailyMed sirolimus prescribing information.

The mouse lifespan result#

In the National Institute on Aging Interventions Testing Program, rapamycin given in food beginning at 600 days of age increased survival in genetically heterogeneous mice at three test sites. The 2009 paper reported a 14% increase for females and 9% for males using age at 90% mortality.

That is an important, replicated animal result. It is not a conversion formula for people, and it does not prove that a weekly human prescription produces the same outcome. Later mouse work also found that effects can vary by dose and sex, and some studies separate lifespan extension from improvement across every measure of ageing.

Sources: 2009 ITP paper, NIA ITP overview, and dose-and-sex study.

What human evidence shows—and does not#

A 2024 systematic review found 19 human studies of rapamycin or related rapalogs. It reported improvements in some physiological parameters, but not broad benefits across all systems. The studies varied by drug, population, regimen, and outcome. Increased infections and lipid changes appeared in some participants with ageing-related disease.

The review did not establish that sirolimus extends human lifespan. Findings for everolimus or another rapalog also cannot automatically validate a particular sirolimus regimen.

The PEARL randomized trial enrolled 129 people and is marked completed in ClinicalTrials.gov, but the registry currently shows no posted results. A completed study without posted results should not be described as positive or negative. RESTOR, a newer study of daily versus intermittent mTOR inhibition in older adults, lists an estimated completion in 2028.

Sources: 2024 human systematic review, PEARL registry record, and RESTOR registry record.

| Evidence layer | What it supports | What it does not support | |---|---|---| | FDA-approved label | Known approved uses, administration framework, interactions, and safety warnings | Use for healthy longevity | | ITP mouse studies | Lifespan extension in specific mouse experiments | A human lifespan benefit or human dose | | Human systematic review | Signals in selected ageing-related measures and documented adverse events | A universal benefit or proven long-term safety | | Trial registry | Study design and recruitment/result status | An efficacy conclusion when results are not posted |

Why this page gives no longevity dose#

The previous version presented a weekly milligram range as an established longevity protocol. Current human evidence does not identify a regimen proven to extend life, and prescription decisions depend on indication, formulation, interactions, laboratory monitoring, and individual risk.

“Intermittent” does not mean harmless. Research regimens are not instructions for self-medication, and lower exposure cannot be assumed to eliminate immunologic, metabolic, pulmonary, reproductive, or wound-healing risks.

Do not buy prescription drugs from an unverified seller or use someone else’s medicine. Anyone considering an off-label discussion should use a licensed clinician who can review the current label, medication list, health history, and monitoring needs.

Questions for a licensed clinician#

• What is the clinical objective, and is there evidence that the proposed outcome benefits people like me?
• Is the proposed drug sirolimus or a different rapalog?
• Which approved-label warnings and interactions apply?
• What baseline and follow-up monitoring would be needed?
• What are the stopping rules for adverse effects, infection, procedures, or abnormal results?
• What uncertainty remains about long-term use in otherwise healthy adults?

This is deliberately a question list, not a treatment plan.

Claims that should trigger caution#

Be skeptical when a page or clinic:

• says rapamycin extends lifespan in every species or proves human age reversal;
• converts a mouse result directly into a human regimen;
• treats everolimus and sirolimus evidence as interchangeable;
• promises that intermittent use removes immunosuppression or other label risks;
• advertises a prescriber without disclosing evidence limits and conflicts; or
• cites a trial registry as though unpublished results were known.

Bottom line#

Rapamycin has unusually strong and replicated mouse lifespan evidence. Human research is meaningful but still limited and heterogeneous, and no human trial has shown that sirolimus extends lifespan in healthy people.

For longevity, use remains experimental and off-label. The current prescribing label—not an online protocol—sets the minimum safety context, and decisions belong with a qualified prescriber.